News | Leads Implantable Devices | June 20, 2017

BioTrace Medical's Tempo Lead Shows Stability and Safety in Real-World Performance

Technology enabling earlier ambulation and recovery following TAVR highlighted at TVT 2017, with live cases broadcast to attendees

BioTrace Medical's Tempo Lead Shows Stability and Safety in Real-World Performance

June 20, 2017 — BioTrace Medical Inc. announced that the company’s Tempo Temporary Pacing Lead was featured in an oral presentation and two live cases during the Transcatheter Valve Therapies (TVT) 2017 conference, June 14-17 in Chicago. Tamim Nazif, M.D., director of clinical services of the Structural Heart and Valve Center at NewYork-Presbyterian/Columbia University Medical Center, presented real-world experiences with the Tempo Lead from transcatheter aortic valve replacement (TAVR) cases.

Nazif’s presentation highlighted the safety of the Tempo Lead, with real-world U.S. experience to date demonstrating no dislodgements or perforations, as well as the technology’s reliable pace capture during and after the procedure, facilitating earlier patient ambulation in recovery.

"Our real-world experience with the Tempo Lead is consistent with the excellent results of the New Zealand first-in-human study demonstrating the safety and reliable performance of the device,” said Nazif. "The Tempo Lead may improve the safety of TAVR and other structural heart procedures by reducing complications like cardiac perforation, loss of pacing capture and valve embolization. There may also be opportunities with the Tempo Lead to reduce the length of ICU stay, expedite recovery and reduce permanent pacemaker implantation with a strategy of watchful waiting in patients with transient conduction disturbances.”

Temporary pacing is an important and necessary adjunctive therapy to support patients undergoing TAVR procedures, but can be associated with serious complications including cardiac perforation and dislodgement with loss of pace capture. BioTrace Medical’s Tempo Lead, cleared in October 2016 by the U.S. Food and Drug Administration (FDA), features a unique design that mitigates the risk of these complications and is the only active fixation temporary lead available, according to the company.

Nazif presented an overview of the technology, highlighting three case studies from NewYork-Presbyterian/Columbia University Medical Center’s use of the lead, as well as early U.S. Tempo Lead experience in several hundred cases with no device-related adverse events, no perforations and no dislodgements. In addition, real-world experience shows patients ambulating post-procedure with the Tempo Lead in place, and overall highly favorable operator feedback.

Additionally, Nazif and Susheel Kodali, M.D., co-director of the Structural Heart and Valve Center at NewYork-Presbyterian/Columbia University Medical Center, performed two live TAVR cases using the Tempo Lead, which were broadcast to attendees at TVT 2017.

“The Tempo Lead has become an important part of our TAVR practice, and I believe that due to its stability and safety the use of this innovative technology will become an important adjunct for TAVR procedures,” said Kodali. “Our own experience to date has been consistent with clinical data from the first-in-human study of the device. This technology provides peace of mind, offering stable pacing both during and after the procedure.”

Results from a 2016 multi-center study of 25 patients conducted in New Zealand demonstrated the safety of the Tempo Lead, with no device related adverse events, dislodgements, sustained ventricular arrhythmia or cardiac perforations. Pacing with the Tempo Lead was successful in all treated patients with no loss of pace capture or lead dislodgement. Average procedural pace capture threshold was 0.7±0.5mA. Rapid pacing was successful in all cases with no loss of capture.

Read the article "FDA Clears Temporary Pacing Technology for Transcatheter Aortic Valve and EP Procedures." 

Read the article "First U.S. TAVR Patients Treated With Temporary Pacing Lead." 

 

For more information: www.biotracemedical.com

Related Content

A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th